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Abstract: Hyperammonemia is a true neonatal emergency with high toxicity for the central 
nervous system and developmental delay. The causes of neonatal hyperammonemia are genetic 
defects of urea cycle enzymes, organic acidemias, lysinuric protein intolerance, hyperammonemia– 
hyperornithinemia–homocitrullinemia syndrome, transient hyperammonemia of the newborn, and 
congenital hyperinsulinism with hyperammonemia. In some of these conditions the high blood 
ammonia levels are due to the reduction of N-acetylglutamate, an essential cofactor necessary 
for the function of the urea cycle, or to the reduction of carbamoyl-phosphate synthase-I activ-
ity. In these cases, N-carbamylglutamate (carglumic acid) can be administered together with the 
conventional therapy. Carglumic acid is an analog of N-acetylglutamate that has a direct action 
on carbamoyl-phosphate synthase-I. Its effects are reactivation of the urea cycle and reduction 
of plasma ammonia levels. As a consequence it improves the traditional treatment, avoiding the 
need of hemodialysis and peritoneal dialysis. In this review we evaluate the possible field of 
application of carglumic acid and its effectiveness and safety.
Keywords: hyperammonemia, N-carbamylglutamate, carglumic acid, urea cycle disorder, 
metabolic disorders
Introduction
In humans catabolism of proteins and other nitrogen-containing molecules results in the 
production of nitrogen. Waste nitrogen is excreted largely as urea with smaller amounts 
as creatinine, ammonium ion, amino acids, and other nitrogenous compounds. In the 
brain, ammonia is an important product of the metabolism of the neurotransmitters 
glutamate and aspartate and of the neurotransmitter monoamines. It is also the prod-
uct of the synthesis of glutamate from glutamine in nerve endings. At least some of 
the glutamate released from the nerve endings is neutralized via uptake by the astro-
cytes where it is combined with ammonia to form the electrophysiologically inactive 
molecule glutamine. Despite its central importance in metabolism, high concentrations 
of ammonia are generally toxic, particularly to the central nervous system, and the 
compound must be maintained at relatively low levels in the tissues.
Many inborn errors of metabolism cause increases in blood ammonia levels. 
Hyperammonemia is a condition that can cause neurological complications, coma, 
and even death. Indeed, high concentrations of ammonia may partially saturate the 
“enzymatic detoxifier” of the astrocytes, impeding the brain’s capacity for self-
 protection, which contributes to the neurological dysfunction. Therefore, high levels 
of ammonia are a real emergency and should be treated promptly. First-line treatment 
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consists of reducing catabolism and promoting anabolism, 
by a protein-restriction diet and substituting an oral or 
intravenous high energy source, such as glucose infusion, 
and parenteral lipids administration after exclusion of fatty 
acid oxidation disorder. Because the kidneys clear ammonia 
poorly, its removal from the body must be expedited by for-
mation of compounds with high renal clearance. Ammonia-
scavenging drugs (sodium benzoate, sodium phenylbutyrate, 
and arginine hydrochloride) are at present considered the 
first-line drugs for the treatment of neonatal hyperammone-
mia. However, if the foregoing therapies fail to produce any 
appreciable change in blood ammonia level within a few 
hours, the neonate should be transferred without delay to 
a center with hemodialysis capacity, and continuous veno-
venous hemofiltration, in particular, should be performed.
The administration of N-carbamylglutamate (carglumic 
acid, NCG) has been reported to be of benefit in several 
different conditions presenting with hyperammonemia.1 
NCG is a synthetic analog of N-acetylglutamate (NAG) 
that activates carbamoyl-phosphate synthase I (CPS-I),2 the 
enzyme of the first and rate-limiting step of the urea cycle 
stimulating ureagenesis3 (Figure 1). NCG is able to enter into 
the mitochondria and is not inactivated by cytosolic acylases.4 
For this reason it is an optimal pharmacological substitute; 
on the contrary, the natural NAG is hydrolyzed in vivo by 
acylamino acid acylase.5
In this review we evaluate the field of application and the 
possibility for the treatment of hyperammonemia with NCG.
N-carbamylglutamate  
in urea cycle disorders
The urea cycle represents the principal mechanism of 
ammonia detoxif ication. Five enzymes are required 
for ureagenesis: CPS-I, ornithine transcarbamylase, 
argininosuccinate  synthase, argininosuccinate lyase, and 
arginase. The urea cycle is also regulated by NAG, an 
essential cofactor  necessary for the function of CPS-I. 
NAG is produced in the mitochondrial matrix from 
 glutamate and acetyl coenzyme A by N-acetylglutamate 
synthase (NAGS). Deficiency in any one of these enzymes 
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Figure 1 Schematic representation of the urea cycle and related pathways. 
Abbreviations: ASS, argininosuccinate synthase; ASL, argininosuccinate lyase; ARG, arginase; CPS-I, carbamoyl-phosphate synthase I; MMA, methylmalonic acidemia; NAGS, 
N-acetylglutamate synthase; OTC, ornithine transcarbamylase; PA, propionic acidemia.
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causes a urea cycle disorder which results in ammonia 
accumulation.6
N-acetylglutamate synthase deficiency
A NAGS deficiency is a rare, autosomal recessive urea cycle 
disorder, and was described for the first time by Bachmann 
and colleagues in 1981.7 In this congenital error there is a 
wide range of severity of symptoms, as well as in the age of 
onset. Most frequently, the onset occurs in the early neonatal 
period with the signs and symptoms of hyperammonemia: 
poorly fed, vomiting, and neurological alteration such 
as hypotonia, abnormal movements of limbs, irritability, 
generalized seizures, afterward lethargy, and coma. Late 
forms may present with acute attacks of hyperammonemia 
in a previously healthy individual or with chronic neu-
rological, gastrointestinal, and psychiatric clinical signs. 
The symptoms could be chronic nausea, vomiting, ataxia, 
confusion, and irritability, and in acute cases could lead to 
coma. The laboratory findings show an increase in blood 
levels of ammonia and markedly elevated concentrations 
of glutamine and alanine. In contrast to most of the other 
urea cycle disorders, plasma citrulline and urinary orotic 
acid are normal as well as urine organic acids and blood 
acylcarnitines. These clinical and biochemical features are 
present both in NAGS and CPS-I deficiencies. The diagnosis 
could be confirmed either with determination of NAGS and 
CPS-I activity in liver tissue in presence of arginine or by 
molecular diagnostic analysis.8 The majority of early forms 
have ,5% NAGS residual activity and often have frameshift 
or nonsense mutations. Indeed, the late form presentation is 
associated with partial NAGS deficiency and hypomorphic 
alleles with single amino acid substitutions.8–11 The treatment 
of acute hyperammonemia consists of an intravenous admin-
istration of adequate calories, fluids, and electrolytes and 
in a restriction of protein intake but providing a mixture of 
essential amino acids. NCG is a specific treatment of hyper-
ammonemia due to NAGS deficiency and should be admin-
istered as early possible when it is suspected.12 Also sodium 
benzoate (200–500 mg/kg/24 h), sodium phenylacetate 
(250–500 mg/kg/24 h), and arginine (200–600 mg/kg/24 h) 
should be considered. In case of failure of the above treatment, 
peritoneal dialysis must be initiated. In 1995, Guffon et al 
described a case of a newborn with NAGS deficiency treated 
by NCG; this treatment was initiated on the 25th day of life 
with a total dose of 80–100 mg/kg/day, with optimal results. 
A 1-year follow-up showed an infant with normal somatic and 
neurological development and a good metabolic  balance.13 
In the following years, 3 other cases, 1 neonatal form and 2 
cases of partial NAGS deficiency, were described.14–16 NCG 
was administered (60–100 mg/kg/day in 4 single doses) and 
a decrease of blood ammonia was observed: this enabled 
an increase in protein intake. In 2004, Caldovic et al17 
studied how the incorporation of an isotopic label from 
ammonium chloride into urea increased after the treatment 
with NAG. This study provided strong evidence that NCG 
therapy restores ureagenesis in NAGS deficiency. Later, in 
2008, Tuchman et al presented a stable isotope 13C tracer 
method to measure ureagenesis and evaluate the effect of 
NCG in humans. The results of these investigations showed 
the reduction of plasma ammonia and glutamine levels and 
confirmed that NCG could be an effective treatment for inher-
ited and secondary NAGS deficiency.18 Nordenström et al19 
and Gessler et al12 reported other clinical cases of NAGS 
deficiency and concluded that the immediate treatment of 
hyperammonemia with NCG entails a favorable long-term 
outcome.
Currently NCG is approved in the European Union and 
the United States for the treatment of hyperammonemia 
due to NAGS deficiency. The initial daily dose should be 
100 mg/kg, up to 250 mg/kg if necessary. It should then be 
adjusted individually in order to maintain normal ammonia 
plasma levels.
Carbamoyl-phosphate  
synthase I deficiency
The therapy with NAG in the kinetic variant or partial 
CPS-I deficiency has been discussed by O’Conner et al 
in 1985.2 In 1996 Kuchler et al20 administered NCG in 
an infant on suspicion of a NAGS deficiency. After the 
treatment, the levels of ammonia and glutamine decreased 
to the normal range. The results of liver biopsy showed 
a normal activity of NAGS and a decrement of activity 
of CPS-I. The authors concluded that NCG stimulates 
the remaining CPS-I and increases ureagenesis, for this 
reason NCG might be used in patients with partial CPS-I 
deficiency.
N-carbamylglutamate  
in organic acidemias
Neonatal hyperammonemia can be caused by some organic 
acidemias. Since the 1970s, hyperammonemia has been 
known to be a complication of propionic acidemia (PA) 
and methylmalonic acidemia (MMA), due to an inhibition 
of carbamoyl-phosphate synthesis, the first step of the urea 
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cycle. In fact, in such disorders, propionyl-CoA accumulates 
and inhibits NAGS. The reduced synthesis of NAG, the natu-
ral stimulator of CPS-I, hinders the conversion of ammonia 
to urea in the liver.21
Propionic acidemia
Propionic acid is an intermediate metabolite of branched-chain 
amino acids (valine, theonine, methionine), odd-chain fatty 
acids, and cholesterol degradation. Propionic acid is carboxy-
lated to methylmalonic acid by a mitochondrial biotin-depen-
dent enzyme: propionyl CoA carboxylase. It is composed of 
2 subunits, α and β; the subunit α binds biotin. A failure of 
this enzyme determines the PA (MIM 606054). This inborn 
disease is inherited as an autosomal recessive trait. The genes 
involved are located in the following chromosomal regions 
13q32 and 3q21-q22, and many mutations have been identi-
fied in different patients. Two forms are described based on 
the clinical manifestations: a severe form in which symptoms 
develop during the first days of life, and a milder form in which 
a patient may have an episode of severe ketoacidosis after a 
healthy period. The clinical findings are poor feeding, vomit-
ing, dehydration, hypotonia, lethargy, severe ketoacidosis with 
rapid progress to coma, and death. Laboratory findings during 
the acute attack are a severe metabolic acidosis, hypoglyce-
mia, and hyperammonemia. Propionic acid and methylcitric 
acid are markedly elevated in the blood and urine of infants 
with PA. To reach a definite diagnosis, a measurement of 
the enzyme activity in leukocytes or cultured fibroblasts is 
required. The treatment consists of hydration, correction of 
acidosis, with intravenous glucose, insulin, carnitine, sodium 
benzoate, and vitamin therapy, associated with a hypercaloric 
protein-free diet. Gebhardt et al described 2 patients with PA 
and hyperammonemia who were treated with NCG. Their 
blood ammonia levels were decreased even by the first dose 
of NCG and normalized in a 6-hour period. In both patients 
dialysis was avoided.22 Also Jones and collaborators published 
2 cases of patients with PA and high ammonia levels. The first 
 newborn responded to administration of NCG optimally with 
a fall in plasma ammonia levels. The second patient did not 
respond to NCG therapy, but in this case the dose of NCG 
was lower (25 mg/kg rather than 250 mg/kg).23 Other cases of 
PA treated with NCG have been described since these cases 
were described. In these studies the administration of NCG 
improved detoxification of ammonia.24–27 The effectiveness 
of NCG in decreasing ammonia levels in patients with PA 
was demonstrated by Tuchman et al. They investigated the 
in vivo synthesis of [13C]urea following administration of 
[1-13C]acetate, a stable isotope tracer, and NCG: in the patient 
with PA they observed an increase of 13CO
2
 in breath, of [13C] 
urea in plasma and production of absolute [13C]urea, although 
this was lower than in healthy subjects.18 Similar results were 
published by Ah Mew et al:28 they administered [13C]sodium 
acetate to 7 patients with PA and neonatal hyperammonemia, 
and measured the concentration of 13CO
2
 in blood and 
[13C]urea, before and after the start of NCG therapy. They 
 demonstrated that NCG increases ureagenesis and decreases 
the blood ammonia and glutamine levels in PA patients.
Methylmalonic acidemia
Methylmalonic acid is normally derived from propionic 
acid as part of catabolism of branched-chain amino 
acids, cholesterol, and odd-chain fatty acids. The enzyme 
methylmalonyl CoA mutase converts the L-methylmalonic 
acid to succinic acid. This enzyme requires as a cofactor 
adenosylcobalamin, a metabolite of vitamin B
12
.29 Deficiency 
of enzyme mutase or, less frequently, of adenosylcobalamin 
determines the accumulation of methylmalonic acid in plasma. 
Two forms of mutase apoenzyme deficiencies are identified, the 
mutation mut0 responsible for complete enzyme deficiency and 
mut- responsible for partial enzyme deficiency.30 These patients 
are not responsive to B
12
-vitamin therapy, unlike the patients 
with a defect in the formation of adenosylcobalamin. The 
clinical findings of the patients with MMA due to mut0, mut-, 
and defect in metabolism of vitamin B
12
 are similar. Severe 
forms develop in the first days of life with feeding problems, 
vomiting, hypotonia, metabolic acidemia, and consensual 
tachypnea. Also this condition when not treated promptly may 
progress to coma and death. The milder forms evolve later 
with hypotonia, feeding failure, and developmental delay.31 
Laboratory findings are hyperammonemia and metabolic 
acidosis with increase of methylmalonic acid in blood. In 
addition propionic acid and its metabolites are found in the 
urine. Diagnosis can be confirmed by measuring mutase 
activity in cultured fibroblasts, or by identifying the mutant 
gene. Intravenous treatment must be immediately started 
with carnitine, glucose, insulin, arginine, sodium benzoate, 
and hypercaloric protein-free diet. It has been demonstrated 
that the administration of NCG decreases blood ammonia 
levels. Gebhardt et al described a case of a 6-day-old newborn 
affected by MMA and hyperammonemia (805 µmol/L). After 
the initial conventional treatment and peritoneal dialysis his 
plasma ammonia levels were 610 µmol/L. NCG therapy was 
started and blood ammonia levels dropped to 100 µmol/L 
3 hours after the first NCG dose administration.32 Also Levrat 
et al reported a case of MMA in which the hyperammonemia 
was resolved with insertion of NCG therapy.33
International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
25
Carglumic acid for hyperammonemia
Maple syrup urine disease
Branched-chain amino acids (leucine, isoleucine, and valine) 
are metabolized by a mitochondrial thiamine pyrophosphate 
(vitamin B
1
)-dependent complex enzyme system: branched-
chain α-ketoacid dehydrogenase.34 This enzyme is composed 
of 3 catalytic components, E1  (decarboxylase component, 
formed by 2 subunits E1α and E1β), E2 (acyltransferase 
component), and E3 (dehydrogenase component).35 Deficiency 
of this enzyme determines maple syrup urine disease (MSUD, 
MIM 251000), so called for the typical sweet odor of maple 
syrup found in body fluids, especially urine. Based on clini-
cal manifestation and response to vitamin B
1
 administration, 
5 types of MSUD have been classified.36 All these clinical 
phenotypes are inherited as an autosomal recessive trait. The 
gene for E1α, E1β, E2, and E3 subunits resides on chro-
mosomes 19, 6, 1, and 7, respectively. There is no mutual 
relationship between clinical phenotypes and genotypes. 
The classic MSUD is the most severe form with major clini-
cal findings. At birth the newborns are healthy; the clinical 
manifestations develop in the first week of life. These are 
poor feeding, vomiting, and in the following days lethargy 
and coma may appear. These patients are hypertonic, with 
muscular rigidity and severe  opisthotonos. The neurological 
manifestations are convulsions, hypoglycemia, and cerebral 
edema may also be present.37 In acute state, the neuroimag-
ing may show cerebral edema most frequently in cerebellum, 
dorsal brainstem, cerebral peduncle, and internal capsule. 
In later ages of life hypomyelination and cerebral atrophy may 
be observed. Laboratory findings show increased levels of 
leucine, isoleucine, and valine in plasma; these amino acids 
and their respective ketoacids are elevated in urine and in 
cerebrospinal fluid.38 The definitive diagnosis can be done 
by measuring the enzyme activity in leukocytes or cultured 
fibroblasts. The treatment of acute state is hydration with 
glucose infusion and a high caloric protein-free diet. In 
some patients peritoneal dialysis or hemodialysis are neces-
sary. In 2009 for the first time, Kalkan Ucar et al used NCG 
in a patient with decompensated MSUD.39 These authors 
demonstrated that the administration NCG together with 
conventional therapy decreases the blood levels of ammonia 
and it can be added to improve the acute metabolic decom-
pensation in patients with MSUD.
Isovaleric acidemia
Isovaleric acidemia (MIM 243500) is a rare autosomal 
recessive inborn disease caused by def iciency of 
isovaleryl coenzyme A dehydrogenase (IVD). IVD is a 
mitochondrial flavoenzyme which catalyzes the conversion 
of isovaleryl-CoA to 3-methylcrotonyl-CoA in the leucine 
degradation. Two forms of this disease exist: an acute one 
in which the symptoms develop in early hours of life with 
vomiting, severe metabolic acidosis, lethargy, convulsion, 
and coma,40 and a chronic intermittent form defined by 
episodes of vomiting, dehydration, metabolic acidosis, and 
alteration of mental status; these events develop in the first 
months or years of life. Characteristic “sweaty feet” may 
be present in acute attacks. If untreated, these patients may 
die or may develop severe central nervous system dysfunc-
tions. Laboratory findings during the acute attacks show 
metabolic acidosis, neutropenia, and thombocytopenia. 
Hypocalcemia, hyperglycemia, and moderate to severe 
hyperammonemia may be present in some patients.41 The 
diagnosis is confirmed by the increase of blood levels of the 
isovaleric acid and its metabolites and by the elevations of 
isovalerylglycine and 3-hydroxyisovaleric acid as well as 
other metabolites in urine.42,43 Mass screening in newborn 
is possible by tandem mass spectrometry (MS/MS) for the 
analysis of the acylcarnitine profile in blood spot. The gene 
of IVD has been mapped to chromosome 15q14-15q15. Also 
it is possible to measure the enzyme activity in leukocytes or 
cultured fibroblasts. Today many mutations of this gene have 
been identified.44,45 In acute attacks the treatment consists 
of hydration, correction of metabolic acidosis by infusing 
sodium bicarbonate, promotion of anabolism by increased 
caloric intake (infusing glucose), and reduced leucine 
intake. Treatment must be initiated promptly. The long-term 
treatment is a diet with lower protein intake (1.5 g/kg/day), 
and administration of L-carnitine (100 mg/kg/day) and 
glycine (150–250 mg/kg/day) to prevent the accumula-
tion of isovaleric acid and its toxic metabolites.46 Coude 
et al47 demonstrated in rat hepatocytes that high levels of 
isovaleric acid inhibited ureagenesis due to a decrease in 
NAG levels, causing hyperammonemia. For this reason, in 
patients with isovaleric acidemia associated with hyperam-
monemia the administration of NCG may be added to con-
ventional therapy. A clinical case report of IVA successfully 
treated with carglumic acid was recently communicated by 
Kasapkara et al.48
N-carbamylglutamate  
in hyperinsulinism 
hyperammonemia syndrome
The hyperinsulinism hyperammonemia syndrome (HI/
HA) is an inborn error of metabolism. It was described 
for the first time by Zammarchi et al49 in 1996. HI/HA 
 syndrome is caused by a mutation of the enzyme  glutamate 
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dehydrogenase (GDH) encoded by GLUD1.50 These 
mutations result in higher activity of GDH. About 80% of 
cases are due to de novo mutations; however a dominant pat-
tern has been demonstrated.51 GDH is a mitochondrial matrix 
enzyme, expressed at high levels in liver, kidney, brain, and 
 pancreatic β-cells. It is composed of 6 subunits and oxidizes 
the  glutamate to α-ketoglutarate and ammonia using NAD 
and/or NADP as a cofactor.52 The clinical manifestations 
of affected infants are variable episodes of hypoglycemia 
 associated with hyperammonemia. Hypoglycemia may 
occur with fasting and in response to protein feeding.53,54 
Patients with HI/HA syndrome show a large acute insulin 
response to leucine administration and the blood amino 
acid concentrations are normal. In these children blood 
ammonia levels are persistently elevated between 2 and 
5 times over normal limit, but the hyperammonemia is not 
associated with lethargy, irritability, or coma. Stanley has 
supposed that  overactivity of GDH in the brain decreases 
the levels of glutamate and glutamine, protecting the central 
nervous system from the neurotoxicity of the accumulation 
of these elements.55 In this metabolic disorder the physio-
pathological basis of hyperammonemia is that the gain in 
GDH activity leads to an increase of ammonia levels and 
excessive  oxidation of glutamate reduces the glutamate 
needed for the synthesis of NAG, slowing the urea cycle.56 
For hypoglycemia the conventional treatment is diazoxide 
(5–15 mg/kg/day), a K
ATP
 channel agonist. Some studies show 
that NCG is a potential therapy for hyperammonemia.57,58
N-carbamylglutamate in valproate-
induced hyperammonemia?
Valproate-induced hyperammonemic encephalopathy is an 
unusual, but serious, adverse effect of valproic acid treatment 
that can lead to death, and is characterized by a decreasing 
level of consciousness, focal neurological  deficits, cognitive 
slowing, vomiting, drowsiness, and  lethargy. The mechanism 
by which hyperammonemia  develops is still unclear. 
 Hyperammonemia may result from the stimulation of 
 kidney glutaminase in the renal cortex, from the depletion of 
mitochondrial acetyl CoA, and decreased  production of NAG, 
but also from the accumulation of propionate, a valproate 
metabolite. The reduction of hepatic NAG, the obligatory 
activator of the first enzyme of the urea cycle, leads to the 
inhibition of hepatic mitochondrial CPS-I.59
Two patients with valproate-induced hyperammonemia 
have been treated with carglumic acid.60 NCG was effective 
in decreasing blood ammonia levels and its administration 
may be added to conventional therapy, as suggested by recent 
guidelines.61
Side effects
The most common adverse reactions (occurring in more than 
13% of patients) observed in patients receiving NCG, regard-
less of causality, are vomiting, abdominal pain, pyrexia, 
tonsilitis, anemia, ear infection, diarrhea, nasopharyngitis, 
and headache. In newborns, NCG is usually well tolerated 
without significant adverse effects. Tachycardia, profuse 
sweating, increased bronchial secretion, hyperthermia, 
and restlessness have been reported only at a dosage of 
650 mg/kg/day.62
Conclusion
We have described the beneficial effects of NCG to decrease 
blood ammonia levels and to improve ureagenesis in different 
conditions presenting with hyperammonemia. NCG is safe, 
fast acting and easy to administer. Dosing varies depending 
on the clinical condition and indication. Restarting the urea 
cycle, NCG increases ureagenesis and diminishes blood 
ammonia levels. It also improves the acute therapy and thus 
reduces the need for or the duration of peritoneal dialysis and 
hemodialysis. Favorable long-term outcomes in promptly 
treated patients with hyperammonemia suggest the need to 
start the NCG therapy as soon as possible, even before the 
exact diagnosis is set up.26
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